Show simple item record

dc.contributor.authorSclanders, Michelle
dc.date.accessioned2015-09-15T16:10:45Z
dc.date.available2015-09-15T16:10:45Z
dc.date.issued2012-04
dc.identifier.citationSclanders, M. 2013. Targeting growth factors to sites of inflammation:gene therapy for multiple sclerosis. Queen Mary University of london.en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/8723
dc.descriptionPhDen_US
dc.description.abstractDisease progression in Multiple Sclerosis (MS), an autoimmune disease of the CNS, is widely accepted to be due to persistent myelin loss (demyelination) coinciding with lost nerve cells and nerve fibres (neuroaxonal loss). Current treatments are immunomodulatory and do not address the neuroaxonal or demyelinating pathology of the disease. It is hypothesised that a lack of growth factors within the CNS may result in the failure of remyelination. Therefore, biologics such as recombinant therapeutic proteins used for gene therapy offer a promising therapeutic intervention to the progressive stages of the disease. However, due to the short half-lives of these therapeutics and their pleiotropic effects, there is cause for concern over their safety and efficacy. Using LAP technology (the fusion of the therapeutic protein with the latent associated peptide [LAP] of TGFβ), the half-life of the therapeutic protein can be increased and can be targeted to sites of inflammation and disease. This study aimed to investigate the potential neuroprotective, remyelinating and anti-inflammatory effects of latent versions of the growth factors erythropoietin (EPO), insulin-like growth factor 1 (IGF1) and transforming growth factor beta (TGF) respectively. Firstly, using molecular cloning techniques, these growth factors were individually fused and linked to the LAP of TGF via a matrix metalloproteinase (MMP) cleavage site resulting in three latent growth factors. Secondly, these latent growth factors were shown to be expressed, and to be biologically active in vitro when released by MMP cleavage. Finally, syngeneic fibroblasts were engineered to express the latent growth factors. It was found that, in CREAE, the fibroblasts engineered to produce latent TGF significantly reduced the disease clinical score as compared to controls whilst latent EPO produced by transduced fibroblasts failed to exert a statistically significant effect on disease progression. Nonetheless, this study demonstrates the feasibility of the latency platform technology to generate latent therapeutics with the ability to act as an intervention to disease progression in MSen_US
dc.language.isoenen_US
dc.publisherQueen Mary University of Londonen_US
dc.subjectMedicineen_US
dc.subjectBiochemical Pharmacologyen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectJoint Inflammationen_US
dc.titleTargeting growth factors to sites of inflammation:gene therapy for multiple sclerosis.en_US
dc.typeThesisen_US
dc.rights.holderThe copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the authorherapy for multiple sclerosis


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • Theses [2958]
    Theses Awarded by Queen Mary University of London

Show simple item record